[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612682":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":19,"responsibleParty":26,"collaborators":28,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":19,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":19,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":19,"overallStatus":51,"whyStopped":19,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":19},{"fullName":5,"class":6},"Shanghai Juncell Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"GC203 TIL","EXPERIMENTAL","participants with advanced solid tumors using cryopreserved GC203 TIL",[13],"Biological: GC203 TIL",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","A tumor sample is resected from each participant and cultured ex vivo to expand the population of engineered tumor infiltrating lymphocytes injection (GC203 TIL). After lymphodepletion, patients are infused GC203 TIL.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Ying Cheng","CONTACT","+8621-69110327","ying.cheng@juncell.com",{"type":27,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[29],{"name":30,"class":31},"Shenzhen Hospital of Southern Medical University","OTHER","100612682","phase-1-a-study-of-gc203-til-in-advanced-solid-tumors-nf-100612682",false,"NCT07256756","A Study of GC203 TIL in Advanced Solid Tumors (NF)","A Phase I Study of Engineered Tumor Infiltrating Lymphocytes Injection (GC203 TIL) in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* have one the tumor resection for gene-edited GC203 TIL production and successfully produced；\n* Age: 18 years to 75years;\n* Histologically diagnosed as solid tumor;\n* Expected life-span more than 3 months;\n* ECOG score 0-1;\n* Test subjects have failed standard treatment regimens, and be willing to receive engineered GC203 TIL therapy;\n* At least 1 evaluable tumor lesion;\n\nExclusion Criteria:\n\n* with other malignant tumors,except for the malignancies that have been cured, have been inactive for ≥5 years prior to study inclusion and have a very low risk of recurrence; Non-melanoma skin cancer or malignant lentigo with adequate treatment and no evidence of disease recurrence; Carcinoma in situ with adequate treatment and no evidence of disease recurrence;\n* Need glucocorticoid treatment, and daily dose of Prednisone greater than 10mg(or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment;\n* Breathe indoor air in a quiet state, and the oxygen saturation of finger pulse is \\\u003C 95%;\n* Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and\u002For anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;\n* Significant cardiovascular anomalies","ALL","18 Years","75 Years",{"count":43,"type":44},8,"ESTIMATED","INTERVENTIONAL",[47],"PHASE1","This study is a prospective, open-label, single-arm clinical trial aimed at evaluating the safety and efficacy of GC203 TIL therapy in treating malignant solid tumors that have failed standard treatment.",[50],"Solid Tumors, Adult","NOT_YET_RECRUITING","2025-12-16",{"date":54,"type":55},"2025-12-23","ACTUAL",{"date":57,"type":44},"2026-01-30",{"date":59,"type":44},"2028-11-30",{"name":5,"class":6}]